Houghten Pharmaceuticals, Inc.

Trega Biosciences, Inc.

Patricia A Weber

Richard Allen Houghten

Mark J Suto

Ronald R Tuttle

Beverly E Girten

Amaresh Basu

Costas C Loullis

Paul Omholt

Ronald Hans Plasterk

Patrick Fagan

Ali Andalibi

Ramon A Puras Lutzke

The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.

Cytokine regulatory agents and methods of use in pathologies and

The present invention provides viral integrase inhibiting peptides having the general structure, ##STR1## where Xaa is an amino acid or an amino acid analog, the stereochemistry of the amino acids or amino acid analogs can be D-amino acids or L-amino acids and the amino and carboxy termini of the peptide can be modified. The invention also provides viral inhibiting peptides having essentially the amino acid sequence, ##STR2## The invention also provides a pharmaceutical composition comprising a viral integrase inhibiting peptide and methods of using a viral integrase inhibiting peptide in vitro or in vivo to reduce or inhibit viral integrase activity in a cell and the infectivity of a virus.

Viral integrase inhibiting peptides

The present invention provides antiviral peptides having the general structure, Arg-Arg-Trp-Trp-Cys-Arg-X, where X is an amino acid or an amino acid analog, the stereochemistry of the amino acids or amino acid analogs can be (D)- or (L)-amino acids and the amino and carboxy termini of the peptide can be modified. The invention also provides a pharmaceutical composition comprising an antiviral peptide and methods of using an antiviral peptide in vitro or in vivo to reduce or inhibit a herpes simplex virus infection.

Antiviral peptides

Growing community of inventors

San Diego, CA, United States of America

Patricia A Weber